Epilepsy in Neurodegenerative Diseases

Epilepsy in Neurodegenerative Diseases

Overview

Epilepsy and seizure activity represent underappreciated complications of neurodegenerative diseases. Emerging evidence indicates that epileptiform activity occurs in 10-22% of Alzheimer's disease patients and represents a significant comorbidity in Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. This bidirectional relationship suggests shared pathophysiological mechanisms between neurodegeneration and hyperexcitability[@vossel2013][@born2015].

The intersection of epilepsy and neurodegeneration represents a growing clinical concern. Historically, seizures were considered late-stage complications of dementia. However, modern EEG studies reveal that subclinical epileptiform activity occurs much earlier in disease progression, potentially contributing to cognitive decline. This insight has profound implications for early detection, treatment strategies, and understanding of disease mechanisms.

Pathway Diagram: Epilepsy-Neurodegeneration Interface

```mermaid
flowchart TD
A["Amyloid-beta Accumulation"] --> B["Synaptic Dysfunction"]
A --> C["Calcium Dysregulation"]
B --> D["Excitatory-Inhibitory Imbalance"]
C --> D
D --> E["Neuronal Hyperexcitability"]
E --> F["Subclinical Epileptiform Activity"]
E --> G["Clinical Seizures"]
F --> H["Accelerated Tau Pathology"]
G --> H
G --> I["Cognitive Decline Progression"]
H --> J["Network Dysfunction"]
J --> K["More Severe Neurodegeneration"]
I --> K

Epilepsy in Neurodegenerative Diseases

Overview

Epilepsy and seizure activity represent underappreciated complications of neurodegenerative diseases. Emerging evidence indicates that epileptiform activity occurs in 10-22% of Alzheimer's disease patients and represents a significant comorbidity in Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. This bidirectional relationship suggests shared pathophysiological mechanisms between neurodegeneration and hyperexcitability[@vossel2013][@born2015].

The intersection of epilepsy and neurodegeneration represents a growing clinical concern. Historically, seizures were considered late-stage complications of dementia. However, modern EEG studies reveal that subclinical epileptiform activity occurs much earlier in disease progression, potentially contributing to cognitive decline. This insight has profound implications for early detection, treatment strategies, and understanding of disease mechanisms.

Pathway Diagram: Epilepsy-Neurodegeneration Interface

Introduction

The intersection of epilepsy and neurodegeneration represents a growing clinical concern. Historically, seizures were considered late-stage complications of dementia. However, modern EEG studies reveal that subclinical epileptiform activity occurs much earlier in disease progression, potentially contributing to cognitive decline.

This connection is bidirectional: not only do neurodegenerative diseases cause seizures, but seizure activity may also accelerate neurodegenerative processes. This creates a vicious cycle where hyperexcitability and neurodegeneration reinforce each other, making early intervention critically important.

Alzheimer's Disease and Epilepsy

Prevalence and Clinical Features

Epilepsy in Alzheimer's disease is more common than previously recognized[@palop2009]:

• Clinical seizures: 10-22% of AD patients develop clinical seizures
• Subclinical epileptiform activity: Detected in up to 40% with continuous EEG monitoring
• Temporal distribution: Seizures typically occur in early-to-mid disease stages
• Seizure types: Myoclonic seizures are particularly common
• Focal impaired awareness: Often subtle focal seizures may be mistaken for cognitive fluctuations

Mechanisms Linking Aβ to Hyperexcitability

Multiple mechanisms connect amyloid-beta accumulation to neuronal hyperexcitability[@amyloidepileps]:

• Enhanced glutamate release from presynaptic terminals
• Reduced GABA release from inhibitory interneurons
• AMPA/kainate receptor alterations
• NMDA receptor dysfunction

• Increased intracellular Ca²⁺
• Enhanced neuronal excitability
• Trigger for pathological cascades

• Parvalbumin-positive interneurons particularly vulnerable
• Reduced perisomatic inhibition
• Network disinhibition

• Aberrant excitatory connectivity
• Hyperexcitable circuits
• Epileptiform activity generation

Tau Pathology and Epilepsy

Tau pathology also contributes to hyperexcitability[@tau2021]:

• Tau loss from axons leads to hyperexcitability
• Tau pathology spreads along circuits
• Hippocampal sclerosis can result
• Tau and Aβ have synergistic effects

Excitatory-Inhibitory Imbalance

The fundamental mechanism involves disrupted excitation-inhibition balance[@gabaergic2019]:

• Reduced GABAergic inhibition: Loss of inhibitory interneurons
• Enhanced glutamatergic excitation: Increased excitatory neurotransmission
• Altered ion channel function: Voltage-gated channel dysfunction
• Network-level changes: Circuit reorganization

Calcium Dysregulation

Intracellular calcium dysregulation links neurodegeneration and hyperexcitability[@calcium2028]:

• Elevated baseline calcium in neurons
• Impaired calcium buffering
• Enhanced glutamate release
• Activation of calcium-dependent kinases

Parkinson's Disease and Epilepsy

Clinical Presentation

Seizures in Parkinson's disease are less common than in AD but still significant[@pdmci2020]:

• Prevalence: ~5-10% of PD patients
• Timing: Often associated with disease progression
• Associated factors: Related to dopaminergic medication use and disease severity
• Cortical involvement: May relate to Lewy body pathology in cortical regions

Mechanisms

Several mechanisms contribute to seizures in PD[@pdseizures2021]:

Treatment Considerations

PD patients with seizures require special consideration:

• Medication interactions: Anti-epileptics and PD drugs may interact
• Dopamine responsiveness: Seizure medications should not worsen PD
• Levodopa absorption: Some AEDs affect levodopa pharmacokinetics

Frontotemporal Dementia

FTD and Epilepsy

Epilepsy is more common in FTD than AD in some studies[@cretin2016]:

• Prevalence: ~15-25% in certain FTD subtypes
• Subtype variation: Higher in some genetic forms
• Age of onset: Younger patients more affected

Progranulin Links

GRN (Progranulin) mutations are particularly associated with epilepsy[@grn2020]:

• Progranulin regulates neuronal excitability
• TDP-43 pathology affects synaptic function
• Earlier onset epilepsy in GRN carriers

C9orf72 and Seizures

The C9orf72 hexanucleotide repeat expansion, common in ALS-FTD, shows strong seizure association[@c9orf722021]:

• High seizure prevalence: Particularly in ALS-FTD overlap
• Mechanisms: RNA toxicity, dipeptide repeat proteins
• Early onset: Seizures can precede motor symptoms

Amyotrophic Lateral Sclerosis

ALS and Epilepsy

Seizures are reported in ALS patients, particularly with specific genetic backgrounds[@alsseizures2019]:

• C9orf72 expansions: Strongest association
• SOD1 mutations: Variable seizure risk
• FUS mutations: May have seizure predisposition

Mechanisms

The mechanisms involve:

• Shared pathology: TDP-43 inclusions affect cortical neurons
• RNA toxicity: Both C9orf72 and FUS related to RNA dysregulation
• Network dysfunction: Motor and extra-motor network involvement

Shared Mechanisms

Excitatory-Inhibitory Imbalance

The common pathway involves disrupted excitation-inhibition balance:

• Reduced GABAergic inhibition
• Enhanced glutamatergic excitation
• Altered ion channel function

Calcium Dysregulation

Intracellular calcium dysregulation links neurodegeneration and hyperexcitability:

• Elevated baseline calcium in neurons
• Impaired calcium buffering
• Enhanced glutamate release
• Trigger for excitotoxicity

Network Hyperexcitability

Synchronized neuronal firing patterns emerge from[@network2020]:

• Loss of inhibitory interneurons
• Synaptic rewiring
• Homeostatic plasticity failures
• Aberrant oscillations

Sleep and Epilepsy

Sleep disruption is both a cause and consequence of epileptiform activity[@sleep2021]:

• Sleep deprivation can trigger seizures
• Interictal discharges increase during sleep
• REM sleep particularly affected
• Bidirectional relationship with neurodegeneration

Therapeutic Implications

Antiepileptic Drug Selection

Special considerations in neurodegenerative disease[@treatment2023]:

| Drug | Advantages | Concerns |
|------|------------|----------|
| Levetiracetam | Good cognitive profile, no hepatic interactions | Behavioral effects possible |
| Lacosamide | Good tolerability | Limited data in neurodegeneration |
| Valproic acid | Multiple mechanisms | Cognitive effects,interactions |
| Lamotrigine | Mood stabilizing | Slow titration |
| Brivaracetam | Similar to levetiracetam | Limited evidence |

Drugs to avoid:

• Topiramate: Cognitive impairment
• Phenytoin: Neurotoxicity risk
• Phenobarbital: Cognitive effects
• Carbamazepine: May worsen Parkinsonism

Disease-Modifying Considerations

Anti-epileptic treatment may influence neurodegeneration:

• Neuroprotective AEDs: Levetiracetam shows promise
• Calcium channel blockers: Some benefit
• Anti-inflammatory effects: Certain AEDs may help

Future Directions

Diagnostic Considerations

EEG Patterns

Characteristic EEG findings in neurodegenerative disease:

• Temporal lobe discharges: Common in AD
• Generalized spike-wave: Less common
• Focal slowing: Often in temporal regions
• Background slowing: Correlates with disease severity

Biomarkers

Several biomarkers may indicate epileptogenic risk[@biomarkers2020]:

• CSF tau: Elevated in AD with seizures
• Neurofilament light chain: Indicates neuronal injury
• EEG biomarkers: Quantitative EEG measures
• MRI: Hippocampal sclerosis detection

Clinical Monitoring

Guidelines for monitoring:

• Routine EEG: Consider in cognitive fluctuations
• Ambulatory EEG: For spell characterization
• Continuous EEG: In refractory cases
• Cognitive monitoring: Track treatment effects

Cross-Linking

• [Neuronal Hyperexcitability](/mechanisms/neuronal-hyperexcitability)
• [Network Oscillation Dysfunction](/mechanisms/network-oscillation-dysfunction)
• [Amyloid Pathology](/mechanisms/amyloid-pathway)
• [Tau Pathology](/mechanisms/tau-pathology-ad)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)